Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis - PubMed
5 hours ago
- #nasal spray
- #allergic rhinitis
- #clinical trial
- Study evaluates GSP301, a combination nasal spray of olopatadine and mometasone, for seasonal allergic rhinitis (SAR).
- Multicenter, randomized, double-blind study with 534 moderate-to-severe SAR patients over 14 days.
- GSP301 showed significant improvement in nasal symptoms (rTNSS) compared to olopatadine or mometasone alone.
- Secondary benefits included improvements in ocular symptoms (rTOSS, iTOSS) and quality of life (RQLQ).
- GSP301 reduced inflammatory markers (IL-5, ECP) in nasal secretions.
- Safety profile was comparable across GSP301, olopatadine, and mometasone groups.
- Conclusion: GSP301 is superior in efficacy and safety for moderate-to-severe SAR treatment.